EXCLUSIVE Sartorius in $11 bln bid for COVID vaccine reagent vendor Maravai -sources

Laboratory supplies vendor Sartorius AG has approached Maravai LifeSciences Holdings Inc , a U.S. provider of capping reagents for COVID-19 vaccines, with an $11 billion acquisition offer, people familiar with the matter said. Maravai rejected the $42 per share all-cash offer from Goettingen, Germany-based Sartorius earlier this month as inadequate, the sources said. It is not clear whether Sartorius will return with a new offer or whether Maravai will attract acquisition interest from other laboratory equipment and supplies providers.